Free cash flow remains structurally negative, with quarterly outflows reaching $2.8 million in 2026Q1, highlighting a critical disconnect between operational scale and cash burn.
| Cash from Operations | -7.99M | -6.85M | -5.65M | -4.54M | -1.01M | -649.11K | -167.3K |
| Operating CF Margin % | - | -681.18% | -929.61% | -1791.56% | -452.48% | -55.94% | -7.67% |
| Operating CF Growth % | -122.43% | -21.26% | -24.33% | -349.8% | -55.6% | -287.99% | - |
| Net Income | -7.58M | 0 | -7.96M | -3.77M | -6.18M | -4.26M | -3.05M |
| Depreciation & Amortization | 66.08K | 0 | 63.74K | 100.37K | 78.79K | 71.78K | 27.86K |
| Stock-Based Compensation | 111.96K | 0 | 3.61M | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -2.06M | -6.84M | -1.56M | -1.28M | 1.78M | 642.92K | 425.74K |
| Working Capital Changes | -641.24K | -5.5K | 192.72K | 405.36K | 3.31M | 2.9M | 2.43M |
| Change in Receivables | 152.41K | -22.9K | -255.42K | -185.37K | 100.4K | 713.06K | -660.28K |
| Change in Inventory | -137.36K | -465.84K | 23.41K | 212.75K | -52.94K | 312.23K | 190.78K |
| Change in Payables | 240.91K | 491.08K | 501.41K | -214.73K | 169.99K | -844.67K | 796.29K |
| Cash from Investing | -254.04K | 254.92K | -1.89M | -115.89K | -60.13K | -35.39K | -70.98K |
| Capital Expenditures | -198.49K | 0 | -103.77K | -57.62K | -60.13K | -3.07K | -70.98K |
| CapEx % of Revenue | 19.77% | 21.69% | 17.08% | 22.72% | 26.94% | 0.26% | 3.25% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -55.55K | 254.92K | -77.34K | -58.27K | 0 | -32.32K | 0 |
| Cash from Financing | 8.11M | 6.44M | 7.05M | 6.47M | 1.22M | 611.23K | 277.36K |
| Debt Issued (Net) | 0 | 0 | 0 | -961.11K | 1.1M | 611.23K | 277.36K |
| Equity Issued (Net) | 8.13M | 6.46M | 7.04M | 6.45M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -18K | -18K | 10.96K | 981.35K | 116.71K | 0 | 0 |
| Net Change in Cash | -113.74K | -149.29K | -483.13K | 1.88M | 149.47K | -76.3K | -95.17K |
| Free Cash Flow | -8.22M | -7.07M | -5.83M | -4.66M | -1.07M | -684.5K | -238.28K |
| FCF Margin % | -818.31% | -702.87% | -959.42% | -1837.26% | -479.42% | -58.99% | -10.92% |
| FCF Growth % | -30.79% | -21.24% | -25.12% | -335.36% | -56.34% | -187.27% | - |
| FCF per Share | -4.76 | -10.54 | -51.29 | -4.71 | -0.74 | -0.47 | -0.16 |
| FCF Conversion (FCF/Net Income) | 1.08x | 0.93x | 0.71x | 1.21x | 0.16x | 0.15x | 0.06x |
| Interest Paid | 0 | 0 | 8.77K | 179.12K | 2.19K | 0 | 0 |
| Taxes Paid | 0 | 0 | 2K | 1K | 1K | 750 | 1.25K |
Imminent liquidity exhaustion
According to the provided cash flow data, SXTP consistently reports operating cash outflows that exceed net losses, as evidenced by the 2026Q1 OCF/NI ratio of 1.31, suggesting that the company's accrual-based accounting fails to capture the full extent of its ongoing cash-based operational burn.
The recurring divergence between net income and operating cash flow indicates that the company is struggling to convert its reported activity into tangible liquidity. This pattern suggests that non-cash adjustments are insufficient to mask the underlying cash-draining nature of the current commercialization phase.
As reported in financial statements, SXTP has maintained a consistently negative free cash flow trajectory, with quarterly outflows reaching $2.8 million in 2026Q1, highlighting a structural inability to generate self-sustaining cash flows from its current commercial operations despite the launch of Arakoda.
The persistent negative FCF margins, which hit -17.1% in the most recent quarter, imply that the company remains entirely dependent on external financing to fund its operations. Investors should monitor whether the company can achieve a pivot toward positive cash generation before its current liquidity reserves are fully depleted.
Based on the company's reported figures, the ratio of CapEx to revenue has shown extreme volatility, peaking at 72.0% in 2024Q2, which indicates that the firm is forced to commit significant capital to maintain its infrastructure despite failing to achieve meaningful revenue scale.
The high capital intensity relative to revenue suggests that the company is still in a heavy investment phase, likely related to manufacturing or regulatory compliance requirements. This level of spending appears disproportionate to the current market penetration of its primary product, raising questions about the efficiency of its capital allocation.
Data from recent quarterly filings reveals erratic working capital movements, including a significant $554.3K outflow in 2026Q1, which suggests that the company is struggling to manage its cash conversion cycle effectively as it attempts to scale the distribution of its malaria prophylaxis product.
The frequent swings in working capital changes indicate potential inefficiencies in inventory management or collection cycles. Such instability in the cash conversion process may further exacerbate the company's already precarious liquidity position, making it difficult to forecast future cash requirements with any degree of certainty.
Quick answers to the most common questions about buying SXTP stock.
60 Degrees Pharmaceuticals, Inc. (SXTP) generated $-6.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
60 Degrees Pharmaceuticals, Inc. (SXTP) reported negative free cash flow of $7.1M in 2025, indicating capital requirements exceeded cash from operations.
60 Degrees Pharmaceuticals, Inc. (SXTP) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.